These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1724922)

  • 1. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype.
    Coyle JD; Boudoulas H; Lima JJ
    Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic studies of procainamide (PA) and N-acetylprocainamide (NAPA) in healthy subjects.
    Wierzchowiecki M; Michałowska D; Lowicki Z; Ochotny R; Grześkowiak A; Tomaszkiewicz T
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):272-6. PubMed ID: 6161089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of procainamide and its metabolite depending on acetylator phenotype].
    Gawrońska-Szklarz B; Górnik W; Kutrzeba J; Wójcicki J; Zakrzewski J
    Pol Tyg Lek; 1992 Oct 5-12; 47(40-41):921-3. PubMed ID: 1284448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of N-acetylation of procainamide and renal clearance of N-acetylprocainamide by para-aminobenzoic acid in humans.
    Tisdale JE; Rudis MI; Padhi ID; Svensson CK; Webb CR; Borzak S; Ware JA; Krepostman A; Zarowitz BJ
    J Clin Pharmacol; 1995 Sep; 35(9):902-10. PubMed ID: 8786250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetics of procainamide and N-acetylprocainamide in renal failure.
    Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA
    Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transport of procainamide and N-acetylprocainamide from blood into the intestinal lumen and intestinal dialysis by oral activated charcoal in rats with acute renal failure.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1988 Jul; 11(7):504-11. PubMed ID: 2460613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method.
    Atkinson AJ; Ruo TI; Piergies AA; Breiter HC; Connelly TJ; Sedek GS; Juan D; Hubler GL; Hsieh AM
    Clin Pharmacol Ther; 1989 Aug; 46(2):182-9. PubMed ID: 2474402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimethoprim alters the disposition of procainamide and N-acetylprocainamide.
    Kosoglou T; Rocci ML; Vlasses PH
    Clin Pharmacol Ther; 1988 Oct; 44(4):467-77. PubMed ID: 2458879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethoprim inhibition of the renal clearance of procainamide and N-acetylprocainamide.
    Vlasses PH; Kosoglou T; Chase SL; Greenspon AJ; Lottes S; Andress E; Ferguson RK; Rocci ML
    Arch Intern Med; 1989 Jun; 149(6):1350-3. PubMed ID: 2471472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphic acetylation procainamide in man.
    Reidenberg MM; Drayer DE; Levy M; Warner H
    Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mandibular and parotid salivary excretion of procainamide and N-acetylprocainamide after intravenous administration of procainamide to rats.
    Watanabe J; Koyama I; Iwamoto K; Ozeki S
    J Pharm Pharmacol; 1987 Nov; 39(11):912-6. PubMed ID: 2448449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans.
    Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL
    J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the acetylator phenotype on amrinone pharmacokinetics.
    Hamilton RA; Kowalsky SF; Wright EM; Cernak P; Benziger DP; Stroshane RM; Edelson J
    Clin Pharmacol Ther; 1986 Dec; 40(6):615-9. PubMed ID: 3780123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic levels of intravenous procainamide in neonates: a retrospective assessment.
    Moffett BS; Cannon BC; Friedman RA; Kertesz NJ
    Pharmacotherapy; 2006 Dec; 26(12):1687-93. PubMed ID: 17125432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous N-acetylprocainamide disposition kinetics in coronary artery disease.
    Kates RE; Jaillon P; Rubenson DS; Winkle RA
    Clin Pharmacol Ther; 1980 Jul; 28(1):52-7. PubMed ID: 6156049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of procainamide acetylator status.
    Lima JJ; Jusko WJ
    Clin Pharmacol Ther; 1978 Jan; 23(1):25-9. PubMed ID: 618707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.